Stephen Mayo
Director · Allogene Therapeutics, Inc.
- 2026
- Jun 23, 2026
- 4
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Stephen Mayo files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Jennifer Zachary - $25.20M in MRK purchases and sales in the last 12 months
- Richard R. Deluca - $11.29M in MRK purchases and sales in the last 12 months
- Chirfi Guindo - $8.15M in MRK purchases and sales in the last 12 months
- David Michael Williams - $8.13M in MRK purchases and sales in the last 12 months
- Robert M. Davis - $5.60M in MRK purchases and sales in the last 12 months
- Caroline Litchfield - $5.02M in MRK purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Stephen Mayo?
Stephen Mayo is a corporate insider, tracked as Director of Allogene Therapeutics, Inc. (ALLO). InsiderAlpha holds 4 primary Form 4 filings for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Stephen Mayo last file a Form 4?
The most recent primary Form 4 on record is dated 23 June 2026, one of 4 filings going back to 2026.
Has Stephen Mayo been buying or selling stock?
Recorded transactions: 0 open-market purchases and 1 open-market sale ($123K) across all tracked filings.
